Evaluating prescribing and access trends for adalimumab biosimilars in pediatric and adolescent care
American Journal of Health-System Pharmacy · 2026
DOI: 10.1093/ajhp/zxag137 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift American Journal of Health-System Pharmacy, 2026. Verfasst von Megan McNicol und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nationwide Children's Hospital, Columbus, OH, USA. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Adalimumab, Practice Patterns, Physicians'. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Purpose
The expiration of market exclusivity for Humira (adalimumab) in February 2023 led to the introduction of 10 biosimilars, raising questions about their impact on prescribing trends, payer responses, and formulary management in pediatrics. The primary objective of this study was to compare time to prior authorization approval between adalimumab biosimilars and the originator product during the first 2.5 years following biosimilar market entry. Secondary objectives were to describe the reason for switching adalimumab products in those already established on adalimumab therapy and to identify reported intolerances associated with biosimilar products.
Methods
To prepare for biosimilar launches, the clinical pharmacy team provided education to clinic staff and the health-system specialty pharmacy (HSSP), engaged with manufacturers to identify resources related to biosimilar products, and established prescribing workflows for patients on adalimumab. An observational study was then conducted from February 1, 2023, to June 30, 2025, across dermatology, gastroenterology, and rheumatology outpatient clinics of an integrated HSSP to assess biosimilar prescribing trends, time to authorization approval, and reason for switches. Included prescriptions were for patients naïve to adalimumab or switching between adalimumab products.
Results
Evaluation of 350 prescriptions for adalimumab-naïve patients found that Humira was the preferred product for 290 prescriptions (82.9%). In adalimumab-naïve patients, the median time to prior authorization approval was 4 days (interquartile range [IQR], 2-9 days), with no significant difference between Humira (4 days; IQR, 2-10 days) and biosimilars (3 days; IQR, 2-9 days; P = 0.39). Among 256 prescriptions for non–adalimumab-naïve patients, the majority (86%) were for switches from Humira to a biosimilar, primarily due to formulary preference (77%), new insurance for the patient (11.3%), or exhaustion of copay card funds (4.7%).
Conclusion
Despite inherent complexities of biosimilar implementation, this study demonstrates that a coordinated, pharmacist-led approach supports timely access to therapy and minimizes treatment delays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nationwide Children's Hospital, Columbus, OH, USA.
- Department of Rheumatology, Nationwide Children's Hospital, Columbus, OH, USA.
- Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH.
- Nationwide Children's Hospital, Columbus, OH, USA.
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, OH.
- Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
ORCID-Profile: Ross M Maltz
Zitieren
APA
McNicol, M., Wise, K., El-Barrad, S., Oberle, E., Taxter, A., Abdel-Rasoul, M., & Maltz, R. M. (2026). Evaluating prescribing and access trends for adalimumab biosimilars in pediatric and adolescent care. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxag137
Vancouver
McNicol M, Wise K, El-Barrad S, Oberle E, Taxter A, Abdel-Rasoul M, et al. Evaluating prescribing and access trends for adalimumab biosimilars in pediatric and adolescent care. American Journal of Health-System Pharmacy. 2026. doi:10.1093/ajhp/zxag137
BibTeX
@article{McNicol2026,
author = {McNicol, Megan and Wise, Kelly and El-Barrad, Salma and Oberle, Edward and Taxter, Alysha and Abdel-Rasoul, Mahmoud and Maltz, Ross M},
title = {Evaluating prescribing and access trends for adalimumab biosimilars in pediatric and adolescent care},
journal = {American Journal of Health-System Pharmacy},
year = {2026},
doi = {10.1093/ajhp/zxag137}
}
EUVIMED